Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — Jul 8, 2026
Galmed Pharmaceuticals reported a net loss of $1.9 million for Q1 2026, widening from a $1.1 million loss in the prior year period, driven primarily by increased R&D expenses of $1.4 million related to clinical trials and pre-clinical studies. The company's cash position declined to $1.6 million from $4.0 million at year-end 2025, resulting in negative operating cash flow of $2.5 million for the quarter. Subsequent to the quarter end, Galmed completed the acquisition of Colospan, a medical device company, for $3.3 million in cash plus an earnout of up to $2.0 million.
Key figures
- Total Debt
- 0
- Total Assets
- 16027000
- Cash Position
- 1600000
- Rd Expenses
- 1360000
- Net Loss Q12025
- 1104000
- Net Loss Q12026
- 1910000
- Sepa Commitment
- 20000000
- Short Term Deposits
- 6080000
- Cash And Equivalents
- 1600000
- Colospan Earnout Max
- 2000000
- Marketable Securities
- 7771000
- Sepa Proceeds Post Period
- 1200000
- Colospan Acquisition Cash Consideration
- 3300000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.